ATE196426T1 - Zyklodextrin-zusammensetzung enthaltend fumagillol-derivate - Google Patents

Zyklodextrin-zusammensetzung enthaltend fumagillol-derivate

Info

Publication number
ATE196426T1
ATE196426T1 AT92110230T AT92110230T ATE196426T1 AT E196426 T1 ATE196426 T1 AT E196426T1 AT 92110230 T AT92110230 T AT 92110230T AT 92110230 T AT92110230 T AT 92110230T AT E196426 T1 ATE196426 T1 AT E196426T1
Authority
AT
Austria
Prior art keywords
composition containing
cyclodextrin composition
fumagillol derivatives
water
pharmaceutical composition
Prior art date
Application number
AT92110230T
Other languages
English (en)
Inventor
Yoshiaki Uda
Yoko Nishida
Yasuaki Ogawa
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE196426T1 publication Critical patent/ATE196426T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT92110230T 1991-06-21 1992-06-17 Zyklodextrin-zusammensetzung enthaltend fumagillol-derivate ATE196426T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP15050791 1991-06-21
JP23048991 1991-09-10

Publications (1)

Publication Number Publication Date
ATE196426T1 true ATE196426T1 (de) 2000-10-15

Family

ID=26480076

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92110230T ATE196426T1 (de) 1991-06-21 1992-06-17 Zyklodextrin-zusammensetzung enthaltend fumagillol-derivate

Country Status (5)

Country Link
US (1) US5486508A (de)
EP (2) EP1004318A3 (de)
AT (1) ATE196426T1 (de)
CA (1) CA2071623C (de)
DE (1) DE69231457T2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0555693B1 (de) * 1992-01-30 2001-09-05 Takeda Chemical Industries, Ltd. Verfahren zur Herstellung hoch-wasserlöslicher Zyklodextrinkomplexe
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5840881A (en) * 1992-11-27 1998-11-24 Takeda Chemical Industries, Ltd. Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility
TW293036B (de) * 1992-11-27 1996-12-11 Takeda Pharm Industry Co Ltd
JPH06157330A (ja) * 1992-11-27 1994-06-03 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物，その製造法と用途
US5684169A (en) * 1992-11-27 1997-11-04 Ensuiko Sugar Refining Co., Ltd. Cyclodextrin inclusion complex of taxol, and method for its production and its use
IL111184A (en) * 1993-10-08 2000-08-13 Farmarc Nederland B V Of Cito Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin
ZA949182B (en) * 1993-12-02 1995-07-26 South African Druggists Ltd Pharmaceutical composition
EP0657176B1 (de) * 1993-12-06 2000-09-20 Takeda Chemical Industries, Ltd. Zusammensetzung mit verbesserter Wasserlöslichkeit, enthaltend eine Wasserunlösliche oder an Wasser schwerunlösliche Verbindung
FR2715307B1 (fr) * 1994-01-25 1996-04-05 Commissariat Energie Atomique Procédé de solubilisation dans un milieu aqueux d'agents antitumoraux de la famille du taxol, et cyclodextrines ramifiées utilisables pour cette solubilisation.
BR9507768A (pt) * 1994-05-27 1997-09-02 Farmarc Nederland Bv Composição farmacêutica
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
FR2741079B1 (fr) * 1995-11-13 1997-12-26 Oreal Nouveaux composes, derives de cyclodextrine et leur utilisation, notamment en cosmetique
HUP9600758A2 (en) * 1996-03-27 1998-03-02 Cyclolab Ciklodextrin Kutato F Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption
NL1003503C2 (nl) * 1996-07-04 1998-01-07 Negma Steba International Dev Farmaceutische samenstelling voor orale toediening.
RU2128664C1 (ru) * 1996-08-14 1999-04-10 Закрытое акционерное общество "Производственно-коммерческая Ассоциация АЗТ" СОЕДИНЕНИЕ ВКЛЮЧЕНИЯ 9-(2-ОКСИЭТОКСИМЕТИЛ)ГУАНИНА С β-ЦИКЛОДЕКСТРИНОМ, ОБЛАДАЮЩЕЕ АНТИГЕРПЕСНОЙ АКТИВНОСТЬЮ
US5942501A (en) * 1996-08-16 1999-08-24 Collaborative Laboratories, Inc. Cyclodextrin derivative complex
US6228997B1 (en) * 1998-07-10 2001-05-08 The United States Of America As Represented By The Secretary Of The Army Transesterification of insoluble polysaccharides
PE20020300A1 (es) * 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
CA2433169A1 (en) * 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Porous substances and methods for producing the same
KR100451485B1 (ko) 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
CN1232539C (zh) * 2002-05-10 2005-12-21 刘云清 有机药物与倍他环糊精衍生物的配合物及其制备方法
CN1870982B (zh) * 2003-10-31 2010-05-26 株式会社钟化 含还原型辅酶q的组合物
PL1729813T3 (pl) 2004-04-01 2011-09-30 Pf Medicament Kompleksy inkluzyjne zawierające piroksykam, cyklodekstrynę i argininę
US20060194762A1 (en) * 2004-12-23 2006-08-31 Olaf Reer Composition comprising an epothilone and methods for producing a composition comprising an epothilone
US20070082870A1 (en) * 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
MX2008012495A (es) 2006-03-28 2009-01-07 Javelin Pharmaceuticals Inc Formulaciones de dosis baja de diclofenaco y beta-ciclodextrina.
CN101002782B (zh) * 2007-01-10 2010-05-19 南京师范大学 含有头孢呋辛酯环糊精包合物的药物组合物及其制备方法
CN101264087B (zh) * 2007-03-14 2010-10-27 南京师范大学 含有头孢泊肟酯环糊精包合物的药物组合物及其制备方法
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
CN106389307A (zh) 2009-05-29 2017-02-15 锡德克斯药物公司 包含环糊精衍生物的可注射美法仑组合物及其制备和使用方法
CN102349872B (zh) * 2011-10-14 2013-05-22 南京威泰珐玛兽药研究所有限公司 一种硫酸头孢喹诺冻干粉针及其制备方法
CN102989003A (zh) * 2012-10-30 2013-03-27 南通原亚精密机械有限公司 口服萘普生-环糊精包合物的制备方法
CN106236722A (zh) * 2016-09-14 2016-12-21 佛山市弘泰药物研发有限公司 一种头孢替安酯分散片的制备方法
CN107080736A (zh) * 2017-03-22 2017-08-22 山东信谊制药有限公司 一种劳拉西泮片的制备方法
CN112724200B (zh) * 2019-10-28 2022-09-27 上海云泽生物科技有限公司 一种稳定环孢霉素a的稀释液及其应用
WO2022058988A1 (en) * 2020-09-21 2022-03-24 Sun Pharmaceutical Industries Limited Parenteral dosage form of diltiazem
AU2023211928A1 (en) 2022-01-25 2024-09-12 Leiutis Pharmaceuticals Llp Novel naproxen sodium preparations for parenteral administration

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5835968A (ja) * 1981-08-28 1983-03-02 Hitachi Ltd 半導体記憶装置
DE3372705D1 (en) * 1982-04-30 1987-09-03 Takeda Chemical Industries Ltd Pharmaceutical composition and its use
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
IT1196033B (it) * 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
JPS62281855A (ja) * 1986-05-29 1987-12-07 Daikin Ind Ltd ビタミン，ビタミン誘導体，またはホルモンを含有する包接化合物
JPH0764884B2 (ja) * 1986-11-27 1995-07-12 株式会社トクヤマ シクロデキストリン組成物
JPH0714328B2 (ja) * 1987-04-07 1995-02-22 昭和産業株式会社 麺類の製造方法
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
ES2059571T3 (es) * 1988-01-19 1994-11-16 Takeda Chemical Industries Ltd Fumagilina como agente angiostatico.
ES2058503T5 (es) * 1988-03-29 1999-04-16 Univ Florida Formulaciones farmaceuticas para uso parenteral.
GB8813682D0 (en) * 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
PH26256A (en) * 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
US4954496A (en) * 1988-08-12 1990-09-04 Fujisawa Pharmaceutical Company, Ltd. Cyclohexane derivatives and pharmaceutical compositions
MY106598A (en) * 1988-08-31 1995-06-30 Australian Commercial Res & Development Ltd Compositions and methods for drug delivery and chromatography.
EP0357061B1 (de) * 1988-09-01 1994-06-08 Takeda Chemical Industries, Ltd. Angiogenese hemmendes Mittel
ATE150750T1 (de) * 1988-09-01 1997-04-15 Takeda Chemical Industries Ltd Fumagillol-derivate
IT1230566B (it) * 1988-10-17 1991-10-28 Vectorpharma Int Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
DE69001187T2 (de) * 1989-03-06 1993-07-08 Takeda Chemical Industries Ltd 6-epifumagillole, ihre herstellung und ihre verwendung.
DE69004598T2 (de) * 1989-03-06 1994-03-24 Takeda Chemical Industries Ltd 6-Amino-6-desoxyfumagillole, ihre Herstellung und ihre Verwendung.
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
EP0415294A3 (en) * 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
TW282399B (de) * 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd

Also Published As

Publication number Publication date
EP0519428A2 (de) 1992-12-23
CA2071623C (en) 2003-04-08
CA2071623A1 (en) 1992-12-22
EP0519428B1 (de) 2000-09-20
EP0519428A3 (en) 1993-05-05
US5486508A (en) 1996-01-23
EP1004318A2 (de) 2000-05-31
EP1004318A3 (de) 2002-08-07
DE69231457D1 (de) 2000-10-26
DE69231457T2 (de) 2001-05-23

Similar Documents

Publication Publication Date Title
DE69231457D1 (de) Zyklodextrin-Zusammensetzung enthaltend Fumagillol-Derivate
MX9203960A (es) Nuevas composiciones farmaceuticas a base de un derivado de taxano.
NO860971L (no) Nye derivater av gamma-cyklodextrin.
PT972762E (pt) Novos analogos estruturais da vitamina d
NL193024B (nl) Piperazinederivaten en farmaceutisch preparaat dat een dergelijk piperazinederivaat bevat.
ATE109145T1 (de) Heterozyklische acylaminothiazolderivate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen.
ATE74003T1 (de) Waessriges pharmazeutisches praeparat.
DE69214704D1 (de) Stabilisiertes Vitamin D Arzneimittel
NO891415L (no) Fremstilling av substituerte flavonoidforbindelser og salter og farmasoeytiske preparater derav.
KR960702730A (ko) 벤즈이소티아졸린-3-온 및 크산테인 고무의 안정한 수성 조제물(stable aqueous formulation of benzisothiazolin-3-one and xanthan gum)
ATE118764T1 (de) Persäure-clathrate, ihre herstellung und ihre verwendungen.
NL192832B (nl) 1,8 gebrugde 6-halogeen-4-chinolon-3-carbonzuurderivaten en farmaceutisch preparaat dat een dergelijk derivaat bevat.
ATE93718T1 (de) Shampoo-zusammensetzung.
DE69105915D1 (de) Trizyklische Verbindungen enthaltende Arzneimittel.
DK1211250T3 (da) C10-Taxanderivater samt farmaceutiske præparater
FR2660195B1 (fr) Composition pharmaceutique a macher, antiinflammatoire et/ou analgesique.
DK235089A (da) Anvendelse af aetiprotimodae til fremstilling af et laegemiddel imod virusinfektioner
ES2062125T3 (es) Una composicion farmaceutica que contiene derivados de hidantoina.
DK251289A (da) Avermectinderivater
FR2676364B1 (fr) Composition pharmaceutique a base de derives d'aminobutanone.
ATE276238T1 (de) C7-taxan-derivate und diese enthaltende pharmazeutische zusammenstellungen
FI911097A7 (fi) 2-oksabisyklo/2.2.1/heptaanijohdannaisia ja näitä yhdisteitä sisältävi ä lääkkeitä
DK0424886T3 (da) Markerings- og denatureringsmiddel for vandopløselige organiske opløsningsmidler

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties